FPL 66564

Drug Profile

FPL 66564

Latest Information Update: 22 Jan 2007

Price : $50

At a glance

  • Originator AstraZeneca R&D Charnwood
  • Class Antihypertensives; Heart failure therapies; Small molecules; Vasodilators
  • Mechanism of Action ACE inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute heart failure; Hypertension

Most Recent Events

  • 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed.
  • 11 Jun 1997 No-Development-Reported for Acute heart failure in United Kingdom (IV)
  • 11 Jun 1997 No-Development-Reported for Hypertension in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top